The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study

Summary

This study is an observational prospective cohort study which aims to generate an antibiogram and to assess the clinical responses and outcomes of microbial keratitis patients, treated with empiric topical antimicrobial therapies, with the main objective being to recommend the most effective empiric therapy. Microbial keratitis patients are attending the Cornea Outpatient Clinic at Alexandria Main University Hospital, Alexandria, Egypt.

Conditions

• Bacterial Keratitis
• Fungal Keratitis
• Mixed Bacterial and Fungal Keratitis
• Microbial Keratitis

Interventions

DRUG

Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution

In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

DRUG

Ceftazidime 5% + vancomycin 5%

In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

DRUG

Gentamicin 1.4% + vancomycin 5%

In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

DRUG

Natamycin 5% Oph Susp

In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

DRUG

Voriconazole 1%

In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

DRUG

Natamycin 5% + voriconazole 1%

In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

DRUG

Natamycin 5%+ ceftazidime 5% + vancomycin 5%

In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

DRUG

Voriconazole 1% + ceftazidime 5% + vancomycin 5%

In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

Sponsors & Collaborators

• Alexandria University

  lead OTHER

Principal Investigators

• Nelly M Mohamed, PhD · Associate Professor of Microbiology and Immunology, Alexandria University

• Tamer H Massoud, PhD · Associate Professor of Ophthalmology, Alexandria University

• Noha A Hamdy, PhD · Assistant Professor of Clinical Pharmacy, Alexandria University

• Amira A Nayel, PharmD · Master's student at the Department of Clinical Pharmacy and Pharmacy Practice, Alexandria University

Eligibility

Min Age

1 Year

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-12-31

Primary Completion

2023-01-01

Completion

2023-01-01

Countries

• Egypt

Study Locations